Почетна › Множен миелом › Тексас › Dallas
Клинички испитувања за Множен миелом во Dallas, TX
17 студии за Множен миелом бараат учесници на локации во и околу Dallas (во радиус од околу 30 милји). Отворете ја студијата за да видите кој може да учествува и како да го контактирате тимот.
Официјален текст на студијата (англиски)
Барате учесници за студија? Истакнете ја на врвот од оваа страница — $99 за 30 дена →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Се регрутираФаза 3
- Research Site, Dallas
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 3
- Baylor University Medical Center, Dallas
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 3
- Baylor University Medical Center, Dallas
- UT Southwestern Medical Center, Dallas
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Се регрутираФаза 3
- University of Texas Southwestern Medical Center, Dallas
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 2
- UT Southwestern Medical Center, Dallas
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Се регрутираФаза 1/2
- University of Texas - Southwestern Medical Center /ID# 271914, Dallas
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Се регрутираФаза 3
- Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
- Baylor University Medical Center, Dallas
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Се регрутираФаза 1
- University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Се регрутираФаза 1/2
- Research Site, Dallas
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Се регрутираФаза 3
- Research Site, Dallas
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Се регрутираФаза 1
- Baylor University Medical Center, Dallas
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Се регрутираФаза 1/2
- University of Texas - Southwestern Medical Center /ID# 274360, Dallas
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Се регрутираФаза 1
- Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Се регрутираФаза 1
- University of Texas Southwestern, Dallas
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Се регрутираФаза 2
- University of Texas Southwestern, Dallas
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Се регрутираНабљудувачка студија
- Ut Southwestern, Dallas
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Се регрутираФаза 1
- University of Texas Southwestern Medical Center, Dallas
Испитувања за Множен миелом во други градови
- New York City, NY60 студии
- Boston, MA42 студии
- Atlanta, GA41 студија
- Houston, TX38 студии
- Durham, NC37 студии
- Nashville, TN32 студии
- Denver, CO27 студии
- Rochester, MN24 студии
- St. Louis, MO24 студии
- Columbus, OH24 студии
- Baldwin Park, CA23 студии
- Chicago, IL22 студии
Други студии во Dallas
- Рак на дојка55 студии
- Рак на бели дробови со не-мали клетки52 студии
- Метастатски карцином42 студии
- Срцева слабост42 студии
- Рак (сите типови)37 студии
- Рак на простата36 студии
- Колоректален карцином33 студии
- Дебелина30 студии
- Карцином на јајниците28 студии
- Рак на бешиката27 студии
- Рак на бели дробови27 студии
- Рак на ендометриумот24 студии
Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.